RU2019100068A3 - - Google Patents

Download PDF

Info

Publication number
RU2019100068A3
RU2019100068A3 RU2019100068A RU2019100068A RU2019100068A3 RU 2019100068 A3 RU2019100068 A3 RU 2019100068A3 RU 2019100068 A RU2019100068 A RU 2019100068A RU 2019100068 A RU2019100068 A RU 2019100068A RU 2019100068 A3 RU2019100068 A3 RU 2019100068A3
Authority
RU
Russia
Application number
RU2019100068A
Other versions
RU2019100068A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52628945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2019100068(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2019100068A publication Critical patent/RU2019100068A/ru
Publication of RU2019100068A3 publication Critical patent/RU2019100068A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/006Pressing and sintering powders, granules or fibres

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019100068A 2013-09-06 2014-09-05 Композиции перорально распадающихся таблеток, содержащие кортикостероиды, для лечения эозинофильного эзофагита RU2019100068A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874450P 2013-09-06 2013-09-06
US61/874,450 2013-09-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2016112259A Division RU2678695C2 (ru) 2013-09-06 2014-09-05 Композиции перорально распадающихся таблеток, содержащие кортикостероиды, для лечения эозинофильного эзофагита

Publications (2)

Publication Number Publication Date
RU2019100068A RU2019100068A (ru) 2019-03-22
RU2019100068A3 true RU2019100068A3 (ru) 2022-04-19

Family

ID=52628945

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016112259A RU2678695C2 (ru) 2013-09-06 2014-09-05 Композиции перорально распадающихся таблеток, содержащие кортикостероиды, для лечения эозинофильного эзофагита
RU2019100068A RU2019100068A (ru) 2013-09-06 2014-09-05 Композиции перорально распадающихся таблеток, содержащие кортикостероиды, для лечения эозинофильного эзофагита

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2016112259A RU2678695C2 (ru) 2013-09-06 2014-09-05 Композиции перорально распадающихся таблеток, содержащие кортикостероиды, для лечения эозинофильного эзофагита

Country Status (29)

Country Link
US (4) US10471071B2 (ru)
EP (2) EP3041476B2 (ru)
JP (1) JP6514702B2 (ru)
KR (3) KR102609926B1 (ru)
CN (1) CN105722513B (ru)
AU (1) AU2014315110B2 (ru)
BR (1) BR112016004844B1 (ru)
CA (2) CA2923055C (ru)
CL (1) CL2016000510A1 (ru)
CY (1) CY1122626T1 (ru)
DK (1) DK3041476T3 (ru)
ES (1) ES2764849T5 (ru)
HK (1) HK1225974A1 (ru)
HR (1) HRP20200015T1 (ru)
HU (1) HUE048533T2 (ru)
IL (3) IL305908A (ru)
LT (1) LT3041476T (ru)
MX (1) MX2016002866A (ru)
MY (1) MY179870A (ru)
PL (1) PL3041476T3 (ru)
PT (1) PT3041476T (ru)
RS (1) RS59803B1 (ru)
RU (2) RU2678695C2 (ru)
SA (1) SA516370678B1 (ru)
SG (2) SG10201901677YA (ru)
SI (1) SI3041476T1 (ru)
UA (1) UA119969C2 (ru)
WO (2) WO2015034678A2 (ru)
ZA (1) ZA201702906B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106421797A (zh) 2009-10-01 2017-02-22 艾戴尔医药公司 口服给予的皮质类固醇组合物
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CN107864622A (zh) * 2015-04-01 2018-03-30 鲁平亚特兰蒂斯控股股份公司 用于制造干粉末共混物的方法
WO2017217494A1 (ja) * 2016-06-16 2017-12-21 東和薬品株式会社 口腔内崩壊錠
TWI728172B (zh) * 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
US11344562B2 (en) 2017-08-15 2022-05-31 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
JP7094563B2 (ja) * 2019-08-05 2022-07-04 学校法人松山大学 錠剤及びその製造方法並びに打錠用粉末

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1170188A (en) 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
SE378109B (ru) 1972-05-19 1975-08-18 Bofors Ab
US4080448A (en) 1974-11-13 1978-03-21 Mirsky Louis H Method of treating cellular stress
US4335121A (en) 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
SE8004580L (sv) 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
GB8630913D0 (en) 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
ZA892859B (en) 1988-04-22 1989-12-27 Advanced Polymer Systems Inc Porous particles in preparations involving immiscible phases
US5278175A (en) 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9002375D0 (en) 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
CA2101773A1 (en) 1991-01-31 1992-08-01 Toyoichi Tanaka Interpenetrating-polymer network phase-transition gels
EP0735884B1 (en) 1993-12-20 2000-04-26 Minnesota Mining And Manufacturing Company Flunisolide aerosol formulations
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
DE19606151C2 (de) 1996-02-20 1999-05-12 Losan Pharma Gmbh Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben
ATE477793T1 (de) 1996-06-14 2010-09-15 Kyowa Hakko Kirin Co Ltd Eine im mund schnell zerfallende tablette
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
SE9604486D0 (sv) 1996-12-05 1996-12-05 Astra Ab Novel formulation
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
RO118174B1 (ro) 1997-08-21 2003-03-28 Aventis Pharma Deutschland Gmbh Lac de unghii şi utilizarea acestuia
ATE219658T1 (de) 1998-03-06 2002-07-15 Eurand Int Schnell zerfallende tablette
FR2781156B1 (fr) 1998-07-20 2001-06-29 Lafon Labor Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
IL145983A0 (en) 1999-04-23 2002-07-25 Leo Pharm Prod Ltd Pharmaceutical composition for dermal use, comprising a corticosteroid and a vitamin d or an analogue thereof
ES2274803T3 (es) 1999-09-11 2007-06-01 Glaxo Group Limited Formulacion farmaceutica de propionato de fluticasona.
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US6785841B2 (en) 2000-12-14 2004-08-31 International Business Machines Corporation Processor with redundant logic
US20030050312A1 (en) * 2001-03-12 2003-03-13 Hjorth Thyge Borup Novel tablets and capsules and a process for its preparation
EP2014307A3 (en) 2001-03-13 2010-12-08 Angiotech International Ag Micellar drug delivery vehicles and uses thereof
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
AU2002255321B2 (en) 2001-05-10 2007-05-17 Astellas Pharma Inc. Tablets quickly disintegrating in the oral cavity and process for producing the same
US6656493B2 (en) 2001-07-30 2003-12-02 Wm. Wrigley Jr. Company Edible film formulations containing maltodextrin
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
JP4173670B2 (ja) 2002-03-08 2008-10-29 旭化成ファーマ株式会社 口腔内崩壊製剤
JP4300184B2 (ja) 2002-05-03 2009-07-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリマー性マイクロエマルション
WO2004021997A2 (en) 2002-09-06 2004-03-18 Microbia, Inc. Inhibitors of fungal invasion
WO2004023984A2 (en) 2002-09-13 2004-03-25 Smith C Steven Novel composition and method for treatment of upper respiratory conditions
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2004064810A1 (ja) 2003-01-21 2004-08-05 Nippon Shinyaku Co., Ltd. 口腔内速崩性錠剤
SI1587514T1 (sl) 2003-01-31 2006-10-31 Orexo Ab Hitro ucinkujoc farmacevtski sestavek
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20050009848A1 (en) 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
ES2325591T3 (es) 2004-03-10 2009-09-09 Bayer Schering Pharma Aktiengesellschaft Composiciones que comprenden drospirenona dispersada molecularmente.
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
PT1634586E (pt) * 2004-09-09 2007-04-30 Medinfar Produtos Farmaceutico Comprimidos de domperidona rapidamente dispersíveis em água.
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US20070059361A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CN1985799B (zh) 2005-12-19 2011-11-09 量子高科(北京)研究院有限公司 口腔崩解制剂的制备方法
JP2009521523A (ja) 2005-12-27 2009-06-04 ジュビラント・オルガノシス・リミテッド 口中溶解性医薬組成物およびその製造方法
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP1958613A1 (en) 2007-02-15 2008-08-20 Polichem S.A. Dermal film-forming liquid formulations for drug release to skin
EP2148659A2 (en) 2007-04-13 2010-02-03 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations
US20100216754A1 (en) 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090123390A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
JP2011503113A (ja) 2007-11-13 2011-01-27 メリテイジ ファーマ,インク. 胃腸炎の治療用組成物
US20150231156A1 (en) 2007-11-13 2015-08-20 Meritage Pharma, Inc. Corticosteroid compositions
CA2708152A1 (en) 2007-12-10 2009-06-18 Eurand, Inc Orally disintegrating tablets comprising diphenhydramine
CL2008003827A1 (es) 2007-12-21 2009-07-24 Aptalis Pharmatech Inc Composicion para tabletas de desintegracion oral que comprende al menos una droga ( temazepam), 0,5-3% de un polimero aglutinanete para odt, un alcohol de azucar y/o sacarido, y un desintegrante; metodo para prepararla; util para tratar una enfermedad o condicion como un trastorno del sueño en pacientes con disfagia..
JP2009173552A (ja) 2008-01-21 2009-08-06 Lion Corp 胃腸薬
RS51649B (en) 2008-07-21 2011-10-31 Dr. Falk Pharma Gmbh. PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF THE UPPER DIGESTIVE TRACT
BRPI0917026A2 (pt) 2008-08-08 2016-02-16 Mcneil Ppc Inc uso de sucralose como agente granulador
DK2328553T3 (da) 2008-08-20 2020-08-24 Univ California Corticosteroider til behandling af inflammatoriske sygdomme i mave-tarm-kanalen
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US8348551B2 (en) * 2009-07-29 2013-01-08 Terratherm, Inc. Method and system for treating contaminated materials
CN106421797A (zh) 2009-10-01 2017-02-22 艾戴尔医药公司 口服给予的皮质类固醇组合物
EP2585075B8 (en) 2010-06-24 2021-09-22 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
NZ611467A (en) 2010-12-02 2015-06-26 Aptalis Pharmatech Inc Rapidly dispersing granules, orally disintegrating tablets and methods
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
HUE042009T2 (hu) 2013-12-23 2019-06-28 Dr Falk Pharma Gmbh Optimalizált gyógyszerkiszerelés a nyelõcsõ gyulladásos elváltozásainak kezelésére
US10294517B2 (en) 2014-03-17 2019-05-21 Children's Hospital Medical Center Genetic test for determining susceptibility for eosinophilic esophagitis
US10176301B2 (en) 2014-09-11 2019-01-08 Meritage Pharma, Inc. Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis
US9980975B2 (en) 2015-01-22 2018-05-29 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
WO2019165138A1 (en) 2018-02-21 2019-08-29 Adare Development I, L.P. Methods of managing eosinophilic esophagitis
JP2022550461A (ja) 2019-10-01 2022-12-01 エロディ ファーマシューティカルズ,エル.ピー. 好酸球性食道炎を治療し、カンジダ症を軽減する方法

Also Published As

Publication number Publication date
US11260061B2 (en) 2022-03-01
MX2016002866A (es) 2016-10-26
JP6514702B2 (ja) 2019-05-15
BR112016004844A2 (ru) 2017-08-01
CA2923055A1 (en) 2015-03-12
HRP20200015T1 (hr) 2020-03-20
IL244419B (en) 2022-04-01
AU2014315110B2 (en) 2019-12-12
HUE048533T2 (hu) 2020-07-28
SG11201601663XA (en) 2016-04-28
KR20160058829A (ko) 2016-05-25
KR102609926B1 (ko) 2023-12-05
ES2764849T3 (es) 2020-06-04
UA119969C2 (uk) 2019-09-10
ZA201702906B (en) 2018-12-19
CN105722513A (zh) 2016-06-29
EP3659587A1 (en) 2020-06-03
HK1225974A1 (zh) 2017-09-22
WO2015035114A1 (en) 2015-03-12
DK3041476T3 (da) 2020-01-27
IL244419A0 (en) 2016-04-21
IL291562B1 (en) 2023-10-01
US10471071B2 (en) 2019-11-12
PL3041476T3 (pl) 2020-04-30
SG10201901677YA (en) 2019-03-28
IL291562A (en) 2022-05-01
IL291562B2 (en) 2024-02-01
CL2016000510A1 (es) 2016-09-09
NZ718371A (en) 2021-03-26
US20200016171A1 (en) 2020-01-16
US11166961B2 (en) 2021-11-09
IL305908A (en) 2023-11-01
LT3041476T (lt) 2020-04-10
WO2015034678A2 (en) 2015-03-12
US20220110945A1 (en) 2022-04-14
RU2678695C2 (ru) 2019-01-31
CA2923055C (en) 2020-09-15
RS59803B1 (sr) 2020-02-28
BR112016004844B1 (pt) 2022-04-26
US20210205328A1 (en) 2021-07-08
RU2019100068A (ru) 2019-03-22
AU2014315110A1 (en) 2016-04-21
JP2016529314A (ja) 2016-09-23
EP3041476B1 (en) 2019-11-06
KR20230169421A (ko) 2023-12-15
KR102341165B1 (ko) 2021-12-20
SI3041476T1 (sl) 2020-03-31
MY179870A (en) 2020-11-18
WO2015034678A3 (en) 2015-07-30
ES2764849T5 (es) 2023-05-31
PT3041476T (pt) 2020-01-20
CA3089453A1 (en) 2015-03-12
US20160206627A1 (en) 2016-07-21
CN105722513B (zh) 2021-10-22
EP3041476A4 (en) 2017-04-26
KR20210158858A (ko) 2021-12-31
EP3041476B2 (en) 2023-01-25
SA516370678B1 (ar) 2020-03-08
CY1122626T1 (el) 2021-03-12
RU2016112259A (ru) 2017-10-11
RU2016112259A3 (ru) 2018-05-16
EP3041476A1 (en) 2016-07-13

Similar Documents

Publication Publication Date Title
AP2016009275A0 (ru)
BR102016010778A2 (ru)
BR112014017733A2 (ru)
BR112014017739A2 (ru)
BR112014017855A2 (ru)
BR112014017765A2 (ru)
BR112016001143A2 (ru)
BR112014017669A2 (ru)
BR112014021878A2 (ru)
BR112016014322A2 (ru)
BR112016009522A2 (ru)
BR112014018207A2 (ru)
BR112014017901A2 (ru)
BR112014017722A2 (ru)
BR112014017794A2 (ru)
BR112014017653A2 (ru)
BR112016004709A2 (ru)
BR112016013640A2 (ru)
BR112015015312A2 (ru)
BR112016012607A2 (ru)
RU2019100068A3 (ru)
BR112015016638A2 (ru)
BR112014018353A2 (ru)
BR112014017745A2 (ru)
BR112014024039A2 (ru)